GlassScriptPhysician profile
Stephen J Renzi
NPI 1760456214
$13,378.49
in general payments reported to CMS, 2019-2025
50 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,129 · 2020: $1,353 · 2021: $1,749 · 2022: $1,553 · 2023: $2,163 · 2024: $2,275 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,587 · Education: $8.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,586.60 |
| Education | $8.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,632.10 | 2021-2025 | |
| Pfizer INC. | $1,420.35 | 2019-2025 | |
| Lilly USA, LLC | $1,338.15 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $1,290.59 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,067.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ani Pharmaceuticals, INC. | $753.16 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.64 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $441.04 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $402.56 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $310.21 | 2019-2022 | |
| Allergan, INC. | $289.17 | 2019-2020 | |
| Amarin Pharma, INC. | $263.45 | 2019-2021 | |
| Amgen INC. | $260.26 | 2020-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $234.05 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $202.56 | 2019-2023 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $202.45 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $201.33 | 2022-2025 | Seglentis, Zoryve |
| Lundbeck LLC | $199.86 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $176.00 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $173.42 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $170.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.04 | 2019-2023 | Eliquis |
| Mallinckrodt Enterprises LLC | $158.06 | 2019 | |
| Merck Sharp & Dohme LLC | $155.75 | 2019-2022 | |
| Axsome Therapeutics, INC. | $155.50 | 2023-2025 | Auvelity, Symbravo |
| Antares Pharma, INC. | $129.28 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $99.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $91.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.49 | 2019-2021 | |
| Halozyme INC | $79.92 | 2023 | |
| Verona Pharma, INC. | $77.99 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $76.14 | 2019-2025 | Veozah |
| Eisai INC. | $63.57 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.78 | 2022 | |
| Ferring Pharmaceuticals INC. | $58.54 | 2024-2025 | Rebyota |
| Mallinckrodt Hospital Products INC. | $54.63 | 2020-2021 | |
| Watermark Medical, INC. | $40.08 | 2024 | |
| Abbott Laboratories | $38.27 | 2022-2023 | Freestyle Libre 3 |
| Depuy Synthes Sales INC. | $35.48 | 2022-2024 | Monovisc, Orthovisc |
| Phathom Pharmaceuticals, INC. | $34.96 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $32.93 | 2019 | |
| Biogen, INC. | $32.55 | 2021-2025 | Leqembi |
| Xeris Pharmaceuticals, INC. | $32.18 | 2023-2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $30.76 | 2025 | Inspire |
| Avanir Pharmaceuticals, INC. | $26.50 | 2019 | |
| Organogenesis INC. | $17.33 | 2022 | |
| Tanabe Pharma America, INC. | $16.82 | 2023 | |
| Vanda Pharmaceuticals INC. | $15.83 | 2025 | Fanapt |
| Electromed, INC. | $14.63 | 2024 | Smartvest |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Renzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.